GlobeNewsWire
09 Mar 2026, 21:16 UTC · 32w ago
Impact · against what's priced in
SAB BIO is significantly derisked following a $175 million capital raise involving Sanofi and the advancement of SAB-142 into a Phase 2b registrational study. While the clinical timeline to 2H 2027 creates a long wait for efficacy data, the immediate liquidity risk is eliminated and strategic validation is high.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
SAB Biotherapeutics raised $175 million through an oversubscribed private placement involving institutional investors and Sanofi.
More positive than 99% of claims this week
The company has a cash position providing an operational runway through 2028.
So whatExtended runway reduces the likelihood of dilutive financing rounds in the near term, providing stability for investors.
Continue reading
5 related stories
The company has secured a runway through 2028 via a $175 million oversubscribed private placement and has advanced its lead candidate into a registrational Phase 2b study.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 94% of claims this week
SAB-142 has advanced into a registrational Phase 2b SAFEGUARD study with topline data expected in the second half of 2027.
More positive than 88% of claims this week
Phase 1 clinical data demonstrated a favorable safety profile and redosability for SAB-142 in healthy volunteers and T1D cohorts.
More positive than 80% of claims this week
Which stocks this story touches
More positive than 97% of ticker scores this week
The company reported positive Phase 1 data, successfully raised $175 million in an oversubscribed offering, and is advancing its lead candidate into a Phase 2b study.
More positive than 50% of ticker scores this week
Mentioned as a high-quality institutional investor participating in a financing round for SAB Biotherapeutics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
4h ago
−20.8%
Price is moving against the score
$3.04 vs $3.84 close before publication (Mar 9) · not market-adjusted
SABS chart →
